Success Story: EB1A Approved Despite RFE! Our Firm Secured Success For an Indian Principal Scientist with Direct Premium Service
Client’s Testimonial:
“I had a wonderful experience working with Chen Immigration. My attorney was knowledgeable, patient, and very responsive. I think the lawyers did a great job with the petition letter, collecting all the relevant data and information to make a strong case. They know what they are doing, and their suggestions along the way were very helpful. I thank the team at Chen Immigration for handling my case and guiding me through the whole process with their prompt and detailed responses to my questions. I am waiting for the case to be approved and hope for a successful outcome!”
On September 18th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Principal Scientist in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Principal Scientist
Country of Origin: India
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: September 18th, 2025
Processing Time: 3 months, 26 days (Premium Processing Requested)
Case Summary:
We are pleased to announce the approval of an I-140 EB1A petition for our client, an accomplished researcher in pharmaceutical sciences. With a Ph.D. and M.S. in pharmaceutical sciences, the Client has built a strong record of advancing targeted drug delivery systems and formulations with direct impact on cancer treatment and autoimmune diseases.
Transforming Pharmaceutical Sciences Through Drug Delivery Innovation
The Client’s work is particularly well-known for pioneering targeted liposomal delivery of resveratrol for the treatment of glioblastoma (GBM), one of the most challenging brain cancers. Their broader body of research addresses pressing issues in oncology and chronic disease management, including polymeric micelles to improve solubility and delivery of anticancer drugs, liposome-based immunotherapy for autoimmune conditions, and magnetic liposomes for cancer imaging and therapy. By designing innovative and practical drug delivery systems, the Client has significantly advanced therapeutic strategies that improve efficacy while minimizing side effects.
Scholarly Record and Research Impact
The petition highlighted the Client’s outstanding record of publication and scholarly influence, including:
- 14 peer-reviewed journal articles (6 first- or co-first-authored)
- 1 peer-reviewed conference article
- 8 abstracts (3 first-authored)
- 4 book chapters (3 first-authored)
- 1 first-authored patent and 1 Patent Cooperation Treaty (PCT) application
The Client’s publications have been cited 1,966 times, placing them among the top 1% most highly cited authors in pharmaceutical sciences over the past decade. Their research has not only contributed to advancing therapeutic delivery technologies but has also shaped subsequent studies worldwide. In addition, the Client has served as a peer reviewer at least 21 times, with invitations from some of the most selective and high-impact journals in the field.
Recognition and Support
The strength of the petition was reinforced by four letters of recommendation from leading experts in pharmaceutical sciences, who attested to the originality and global significance of the Client’s contributions.
“It is crucial that she is granted the opportunity to pursue her pioneering work without interruption, ensuring that the United States can fully capitalize on her invaluable contributions to the advancement of the medical sciences and healthcare innovation.”
The Client’s research has also attracted prestigious funding support, including from Hoffmann-La Roche, further underscoring the importance and applicability of their work to pressing healthcare challenges.
A Successful Outcome
USCIS agreed that the Client’s record demonstrated both sustained international recognition and original contributions of major significance, leading to the approval of their EB1A petition. This success underscores their critical role in advancing drug delivery and therapeutic development, with implications for improving cancer care, autoimmune disease treatment, and global health outcomes.
At NAILG, we are proud to have assisted the Client in preparing a strong, evidence-based petition. Their success highlights both their exceptional achievements and our firm’s expertise in navigating the EB1A process. We look forward to seeing their continued contributions to advancing pharmaceutical sciences in the United States.